Role of the endocannabinoid system in the neuroendocrine responses to inflammation

Current Pharmaceutical Design

Volumn 20, Issue 29, 2014, Pages 4697-4706

  De Laurentiis, Andrea ^a   Araujo, Hugo A ^b   Rettori, Valeria ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal gland; Anandamide; Cannabinoid receptors; Cytokines; Hormones; Hypothalamus; Infection; Pituitary

Indexed keywords

ENDOCANNABINOID;

ARTICLE; BRAIN REGION; CELL MEMBRANE; CEREBROVASCULAR ACCIDENT; ENDOCANNABINOID SYSTEM; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; MENTAL STRESS; MICROGLIA; NEGATIVE FEEDBACK; NERVOUS SYSTEM INFLAMMATION; NEUROENDOCRINE SYSTEM; NEUROENDOCRINOLOGY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHYSICAL STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL STRESS; STEROIDOGENESIS; SYNAPTOSOME; TISSUE INJURY; NEUROSECRETION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ENDOCANNABINOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; NEUROSECRETORY SYSTEMS;

EID: 84906226188     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140130212957     Document Type: Article

References (89)

1. Mechoulam R., Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013, 64: 6.1-6.27.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
3. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of the endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012; 204: 207-29.
4. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
5. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
6. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2-3): 173-92.
7. 2+ influx via TRPV1 channels. EMBO J 2005; 24: 3026-37.
8. Jung KM, Mangieri R, Stapleton C, et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 2005, 68: 1196-202.
9. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012; 35: 529-58.
10. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 1995; 270 (40): 23823-7.
11. Okamoto Y, Wang J, Morishita J, Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 2007; 4(8): 1842-57.
12. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2):161-202.
13. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors localization in rat brain: a quantitative in vitro autoradio-graphic study. J Neurosci 1991; 11: 563-83.
14. Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) 2012; 205(1):41-60.
15. Castillo P, Younts TJ, Chávez AE, Hashimotodani Y. Endocan-nabinoid signaling and synaptic function. Neuron 2012; 76: 70-81.
16. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232(1): 54-61.
17. Felder CC, Dickason-Chesterfield AK, Moore SA. The Search for New Cannabinoid Therapeutics. Mol Inter 2006; 6 (3): 149-61.
18. Onaivi ES, Ishiguro H, Gu S, Liu Q. CNS effects of CB2 cannabi-noid receptors: beyond neuro-immuno-cannabinoid activity. J Psy-chopharmacol 2012; 26(1): 92-103.
19. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anan-damide. Nature 1999; 400(6743):452-7.
20. 2+ signalling. Cell Calcium 2009; 45(6): 611-24.
21. Fu J, Bottegoni G, Sasso O, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 2011; 15(1): 64-9.
22. Feledziak M, Lambert DM, Marchand-Brynaert J, Muccioli GG. Inhibitors of the Endocannabinoid-Degrading Enzymes, or how to Increase Endocannabinoid's Activity by Preventing their Hydrolysis. Recent Patents on CNS Drug Discov 2012; 7: 49-70.
23. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270(1): 219-27.
24. Sánchez AJ, Gracía-Merino A. Neuroprotective agents: cannabi-noids. Clin Immunol 2012; 142: 57-67.
25. Souza-Moreira L, Campos-Salinas J, Caro M, Gonzalez-Rey E. Neuropeptides as pleiotropic modulators of the immune response. Neuroendocrinology 2011; 94: 89-100.
26. Elenkov IJ, Wilder RL, Chrousos GP, Vizi S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
27. Blalock JE. The immune system as the sixth sense. J Intern Med 2005; 257: 126-38.
28. Herman JP, Flak J, Jankord R. Chronic stress plasticity in the hypo-thalamic paraventricular nucleus. Prog Brain Res 2008; 170: 353-64.
29. Dongsheng Cai, Tiewen Liu. Hypothalamic inflammation: a double-edged sword to nutritional diseases. Ann NY Acad Sci 2012; 1243: E1-39.
30. Armario A, Daviu N, Muñoz-Abellán C, et al. What can we know from pituitary-adrenal hormones about the nature and consequences of exposure to emotional stressors? Cell Mol Neurobiol 2012; 32(5): 749-58.
31. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to gluco-corticoid receptor dysfunction. Ann NY Acad Sci 2012; 1261:55-63.
32. McDonald NA, Kuzmiski JB, Naderi N, Schwab Y, Pittman QJ. Endogenous modulators of synaptic transmission: cannabinoid regulation in the supraopitc nucleus. Progr Brain Res 2008; 170. In: In: Advances in Vasopressin and oxytocin from genes to behaviour to disease. Neumann ID. and Landgraf R. (Eds.),. Elsevier, Oxford, UK, pp. 129-36.
33. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Research 2000; 886: 172-89.
34. Besedovsky HO, del Rey A. Central and peripheral cytokines mediate immune-brain connectivity. Neurochem Res 2011; 36 (1):1-6.
35. Rivest S. Interactions between the immune and neuroendocrine systems. Prog Brain Res 2010; 181: 43-53.
36. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregula-tory feedback between IL-1 and glucocorticoid hormones. Science 1986; 233: 652-4.
37. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann NY Acad Sci 2012; 1261: 55-63.
38. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function and regulation. Physiol Rev 2001; 81: 629-83.
39. Advances in vasopressin and oxytocin-from genes to behaviour to disease. Progress in Brain Research, vol 170, by Neumann ID and Landgraf R (Eds.) 2008. ISBN 978-0.444-53201-5.
40. Leng G, Ludwig M. Neurotransmitters and peptides: whispered secrets and public announcements. J Physiol 2008; 586(Pt 23): 5625-32.
41. Smith AS, Wang Z. Salubrious effects of oxytocin on social-stress induced deficits. Horm Behav 2012; 61: 320-30.
42. Aguilera G, Subburaju S, Young S, Chen J. The parvocellular vassopresinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog Brain Res 2008; 170. In: Advances in Vasopressin and oxytocin from genes to behaviour to disease. Newman ID and Landgraf R (Eds.). Elsevier, Oxford, UK, pp 29-39.
43. Oliet SHR, Panatier A, Piet R, Mothet JP, Poulain DA, Theodosis DT. Neuron-glia interactions in the rat supraoptic nucleus. Prog Brain Res 2008; 170: 109-17.
44. Theodosis DT. Oxytocin-secreting neurons: A physiological model of morphological neuronal and glial plasticity in the adult hypothalamus. Front Neuroendocrinol 2002; 23(1): 101-35.
45. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999; 57: 625-55.
46. Antunes-Rodriguez J, De Castro M, Elías L, Valenca M, McCann SM. Neuroendocrine control of body fluid metabolism. Physiol Rev 2004; 84: 168-208.
47. De Laurentiis A, Fernandez-Solari JJ, Mohn C, Burdet B, Zorrilla Zubilete M, Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor alpha induced by lipopolysaccharide. J Neuroimmunol 2010; 221: 32-41.
48. Xia Y, Krukoff TL. Differential neuronal activation in the hypothalamic paraventricular nucleus and autonomic/neuroendocrine responses to I.C.V. endotoxin. Neuroscience 2003; 121(1): 219-31.
49. Pittman QJ. A Neuro-Endocrine-Immune Symphony. J Neuroendo-crinology 2011; 23:1296-7.
50. Karelina K, Stuller KA, Jarrett B, et al. Oxytocin mediates social neuroprotection after cerebral ischemia. Stroke 2011; 42(12): 3606-11.
51. Dabrowska J, Hazra R, Ahern TH, et al. Neuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: implications for balancing stress and affect. Psychoneuroendocrinology 2011; 36: 1312-26.
52. Russell JA, Walley KR. Vasopressin and its immune effects in septic shock. J Innate Immun 2010; 2: 446.
53. Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care 2011; 15(4): 226-45.
54. Gorzalka BB, Dang SS. Minireview: Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology 2012; 153(3): 1016-24.
55. Rettori V, Wenger T, Snyder G, Dalterio S, McCann SM. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 1988; 47: 498-503.
56. Wenger T, Rettori V, Snyder GD, Dalterio S, McCann SM. Effects of delta-9-tetrahydrocannabinol on the hypothalamic-pituitary control of luteinizing hormone and follicle-stimulating hormone secretion in adult male rats. Neuroendocrinology 1987; 46: 88-93.
57. Rettori V, Aguila MC, Gimeno MF, Franchi AM, McCann SM. In vitro effect of A9-tetrahydrocannabinol to stimulate somatostatin release and block that of luteinizing hormone-releasing hormone by suppression of the release of prostaglandin E2. Proc Natl Acad Sci USA 1990; 87: 10063-6.
58. Fernandez-Solari J, Scorticati C, Mohn C, et al. Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. Proc Natl Acad Sci USA 2004; 101: 3264-8.
59. Rettori V, Lomniczi A, Mohn C, et al. Mechanisms of inhibition of LHRH release by alcohol and cannabinoids. Prog. Brain Res 2002; 141: 175-81.
60. Scorticati C, Mohn C, De Laurentiis A, et al. The effect of anan-damide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci USA 2003; 100: 2134-9.
61. Scorticati C, Fernández-Solari J, De Laurentiis A, et al. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci USA 2004; 101: 11891-6.
62. Rettori V, De Laurentiis A, Fernandez-Solari J. Alcohol and endo-cannabinoids: neuroendocrine interactions in the reproductive axis. Exp Neurol 2010; 224: 15-22.
63. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008; 170: 397-432.
64. Newsom RJ, Osterlund C, Masini CV, Day HE, Spencer RL, Cam-peau S. Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats. Neu-roscience 2012; 204: 64-73.
65. Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Im-munobiology 2010; 215(8): 629-46.
66. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004; 145: 5431-8.
67. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008; 20: Suppl 1: 35-8.
68. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010; 30(45): 14980-6.
69. Hill MN, McEwen BS. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(5):791-7.
70. Pagotto U, Marsicano G, Fezza F, et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 2001; 86(6): 2687-96.
71. Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endo-crinol Metab 2009; 23: 103-16.
72. Ziegler CG, Mohn C, Lamounier-Zepter V, et al. Expression and function of endocannabinoid receptors in the human adrenal cortex. Horm Metab Res 2010; 42(2): 88-92.
73. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27 (1): 73-100.
74. Sabatier N, Leng G. Presynaptic actions of endocannabinoids mediate alpha- MSH-induced inhibition of oxytocin cells. Am J Physiol Regul Integr Comp Physiol 2006; 290 (3): R577-84.
75. De Laurentiis A, Fernandez Solari J, Mohn C, Zorrilla Zubilete M, Rettori V. The endocannabinoid system participates in the neu-roendocrine control of homeostasis. Neuroimmunomodulation 2010; 17 (3): 153-6.
76. Giusti Paiva A, Kagohara Elías LL, Antunes-Rodriguez J. Inhibitory effect of gaseous neuromodulators in vasopressin and oxytocin release induced by endotoxin in rats. Neurosci Lett 2005; 381: 320-4.
77. Rettori V, Canteros G, Reynoso R, Gimeno M, McCann SM. Oxy-tocin stimulates the release of luteinizing hormone-releasing hormone from medial basal hypothalamic explants by releasing nitric oxide. Proc Natl Acad Sci USA 1997; 94: 2741-4.
78. Neumann ID, Wigger A, Torner L, Holsboer F, Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypo-thalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol 2000; 12(3): 235-43.
79. McCann SM, Antunes-Rodrigues J, Franci CR, Anselmo-Franci JA, Karanth S, Rettori V. Role of the hypothalamic pituitary adrenal axis in the control of the response to stress and infection. Braz. J Med Biol Res 2000; 33 (10): 1121-31.
80. Fernandez-Solari J, Prestifilippo JP, Bornstein SR, McCann SM, Rettori V. Participation of the endocannabinoid system in the effect of TNF-alpha on hypothalamic release of gonadotropin-releasing hormone. Ann NY Acad Sci 2006; 1088: 238-50.
81. Mastronardi CA, Yu WH, McCann SM. Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system. Neuroimmunomodulation 2001; 9: 148-56.
82. Rettori V, Fernandez-Solari J, Prestifilippo JP, et al. Endocannabi-noids in TNF-alpha and ethanol actions. Neuroimmunomodulation 2007; 14: 188-92.
83. Sofia RD, Knobloch LC, Harakal JJ, Erikson DJ. Comparative diuretic activity of delta 9-tetrahydrocannabinol, cannabidiol, can-nabinol and hydrochlorothiazide in the rat. Arch Int Pharmacodyn Ther 1977; 225 (1): 77-87.
84. Tyrey L, Murphy LL. Inhibition of suckling-induced milk ejections in the lactating rat by delta 9-tetrahydrocannabinol. Endocrinology 1988; 123: 469-72.
85. Di S, Boudaba C, Popescu IR, et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J. Physiol 2005; 569: 751-60.
86. Crosby KM, Bains JS. The intrincate link between glucocorticoids and endocannabinoids at stress-relevant synapses in the hypo-thalamus. Neuroscience 2012; 204: 31-7.
87. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.
88. Downer EJ. Cannabinoids and innate immunity: Taking a Toll on Neuroinflammation. The Scientific World Journal 2011; 11: 855-65.
89. Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008; 29(14):1761-71.